Two-dimensional electrophoresis image interpretation.

P M Nugues

doi:10.1109/10.238460

Home/Archive/PubMed

PubMed · 8258442

Two-dimensional electrophoresis image interpretation.

P M Nugues

View original source ↗Export metadata ↓

Abstract

A novel method to interpret two-dimensional electrophoresis gels is presented. Genetic background and electrophoretic processes are summarized. Present methods to analyze gel images and to exploit series of gels are described, then their drawbacks are outlined. Artificial Intelligence techniques are introduced to build an image interpretation system which can compensate for certain failures of present methods and augment their efficiency. By reproducing methods of biological experts, this system automatically identifies proteins--whether isolated or inside constellations--on an electrophoretic gel. This system is based on a modular architecture, featuring image processing procedures, which allows extraction of parameters on the image and a top-down and bottom-up reasoning process. The reasoning process first matches extracted parameters to possible geometric models of proteins; it then returns to the image to determine possible missing elements on the gel. A prototype of this system was implemented and tested on plasma gels to identify apolipoproteins.

Explore related subjects

Apolipoproteins Artificial Intelligence Computer Systems Electrophoresis, Gel, Two-Dimensional Humans Image Interpretation, Computer-Assisted Image Processing, Computer-Assisted Proteins Reproducibility of Results Comparative Study Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

P M Nugues. 1993. Two-dimensional electrophoresis image interpretation.. https://doi.org/10.1109/10.238460

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia.

To evaluate the potential dose effect of rosuvastatin on triglyceride (TG) levels in Japanese hypertriglyceridemic patients, we randomized 154 patients with TG levels of >or=200 and <800 mg/dL to 8 weeks of treatment with rosuvastatin 5, 10 or 20mg once daily; bezafibrate 200mg twice daily; or placebo. Compared with placebo, TG was reduced by 30.1% with rosuvastatin 5mg, 30.1% with 10mg and 32.3% with 20mg (all p<or=0.0001), with no evidence of a dose effect. Changes in TG were evident after 2 weeks of treatment and maintained thereafter. In a benchmark comparison, rosuvastatin across its dose range reduced TG by 29.1-31.1% from baseline versus 45.4% for bezafibrate. Compared with bezafibrate, rosuvastatin was superior with respect to changes in non-high-density lipoprotein cholesterol (non-HDL-C, -36.8 to -44.3% for rosuvastatin versus -2.0% for bezafibrate), low-density lipoprotein cholesterol (-31.9 to -41.0% versus +29.3%), total cholesterol (-27.1 to -33.3% versus +2.1%), although smaller improvements in HDL-C (12.4-16.7% versus 19.6%) were observed. Rosuvastatin also produced superior dose-related decreases in median high-sensitivity C-reactive protein (22.9-38.5%). Treatment was well tolerated in both rosuvastatin and bezafibrate patients, with clinically important increases in alanine aminotransferase being rare, no adverse effect on renal function being observed and no cases of myopathy or rhabdomyolysis being reported. The current study does not suggest a dose-related effect of rosuvastatin in lowering TG in hypertriglyceridemic Japanese patients, although dose-related improvements in other elements of the atherogenic lipid profile were observed.

Apolipoproteins↗

PubMed2007

Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation.

Apolipoprotein M (apoM), a novel human apolipoprotein recently discovered, predominantly presents in high density lipoprotein (HDL) in plasma, exclusively expressed in liver and in kidney. The present data demonstrated apoM protects against atherosclerosis (AS) primarily via partaking in prebeta-HDL formation and promoting cholesterol efflux to HDL. However, this lipid-metabolism-associated pathway seems unlikely responsible for all atheroprotective effects of apoM. Notably, the human apoM gene is just located in the major histocompatibility complex class III region (MHC-III) on chromosome 6, many genes in this region are related to the immune and inflammatory response. Furthermore, apoM has been documented to link with some inflammatory factors including platelet activating factor (PAF) and leptin. These evidences indicate that apoM may be involved in inflammatory activities in vivo and the potential immuno- and inflam-reactive property of apoM may contribute to the anti-inflammatory function of HDL, as generally acknowledged as an important atheroprotective mechanism of HDL.

Apolipoproteins↗

PubMed2007

Disorders in high-density metabolism with insulin resistance and chronic kidney disease.

Cardiovascular risk increases with each decrement in renal function. Low-density lipoprotein (LDL) cholesterol levels are not associated with increased mortality, but high-density lipoprotein (HDL) levels are inversely associated with cardiovascular risk. Lipoprotein composition with increased abundance of small dense LDL and HDL and reduced levels of more buoyant isoforms is similar to what is found in states of insulin resistance and in the metabolic syndrome (MS). In both cases, high triglyceride levels are associated with reduced HDL levels. Chronic kidney disease (CKD) is itself associated with increasing insulin resistance as renal function fails. In both instances, decreased levels of apo A-I and apo A-II are a consequence of increased fractional catabolic rate (FCR), resulting from a predominance of small HDL particles. HDL maturation is impaired in CKD through decreased activity of lecithin:cholesterol acyltransferase (LCAT), and increased cholesterol ester transfer protein (CETP) activity in MS shuttles triglycerides back into HDL, thereby destabilizing it. Whether insulin resistance is entirely responsible for disorders of HDL metabolism in CKD, or whether the process is a result of unrelated pathophysiology, is currently unknown.

Apolipoproteins↗